Researchers at UCLA have discovered a previously unrecognized type of progenitor cell in inflamed areas of the prostate that have the ability to initiate cancer in response to genetic changes.
These are Urology Times' most-read prostate cancer articles of 2016.
Other products discussed include a stent system for treating ureteral obstructions, a male infertility test, and more.
Fewer than 20% of patients with biochemical recurrence after radical prostatectomy develop metastasis, and a smaller proportion die as a result of prostate cancer.
Other pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.
A new approach to prostate cancer screening has been proposed by investigators who claim the idea of informed decision-making by primary care physicians is not working when it comes to PSA testing.
Other new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.
The risk of prostate cancer relapse after radical prostatectomy increases with lengthening delay between diagnosis and surgery. The impact, however, is significant only in high-risk patients, and even in those men, there may be a window of up to 12 months during which it may be relatively safe to postpone surgery, reported researchers from Milan, Italy.
Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
Urologist Henry Rosevear, MD, discusses actor Ben Stiller's recent blog post that credits PSA tests for saving his life after he was diagnosed with prostate cancer and the urologic community's surprising reaction to the article.